Son Chau, MD
Internal Medicine · Orlando, FLNPI 1023006111
Payments from drug & device makers
Across 169 payments — averaging $128.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Gilead$19K
- AstraZeneca$318
- Astellas Pharma US Inc$224
- Watermark Medical, Inc.$172
- GSK$172
- Novo Nordisk$169
- plus $1K from 19 others
What the payments were for
- Consulting fees$2,10010%
- Speaking & faculty fees$13,31061%
- Travel & lodging$2,73713%
- Food & beverage$3,44416%
- Education$1921%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Gilead | 66 | $19,357 |
| AstraZeneca | 21 | $318 |
| Astellas Pharma US Inc | 4 | $224 |
| Watermark Medical, Inc. | 1 | $172 |
| GSK | 4 | $172 |
| Novo Nordisk | 4 | $169 |
| Boehringer Ingelheim | 10 | $163 |
| AbbVie(2 entities) | 6 | $158 |
| Novartis | 7 | $114 |
| Pfizer | 6 | $108 |
| Johnson & Johnson | 6 | $93 |
| Biotronik Inc. | 1 | $92 |
| Hoffmann-la Roche Limited | 1 | $86 |
| Silk Road Medical, Inc. | 1 | $76 |
| Lilly USA, LLC | 6 | $76 |
| Sunovion Pharmaceuticals Inc. | 5 | $71 |
| Amgen | 4 | $69 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 4 | $51 |
| Amarin Pharma, Inc. | 3 | $48 |
| Genentech USA, Inc. | 2 | $44 |
| Merck | 2 | $35 |
| Abbott | 2 | $26 |
| Radius Health, Inc. | 1 | $21 |
| Sanofi-aventis U.S. LLC | 1 | $20 |
| Evoke Pharma, Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Vemlidy$18,166
- TRELEGY ELLIPTA$125
- RYBELSUS$125
How this compares
$21,783 in reported general payments places this provider in the 95th percentile of 8,530 internal medicine providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 360 | $303,495 |
| JanuviaSitagliptin Phosphate | 150 | $170,337 |
| FarxigaDapagliflozin Propanediol | 133 | $165,202 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 197 | $139,589 |
| EliquisApixaban | 137 | $128,337 |
| OzempicSemaglutide | 51 | $61,920 |
| NuplazidPimavanserin Tartrate | 20 | $48,145 |
| ProliaDenosumab | 27 | $46,767 |
| RybelsusSemaglutide | 36 | $41,140 |
| VemlidyTenofovir Alafenamide | 24 | $36,972 |
| Tresiba Flextouch U-100Insulin Degludec | 37 | $34,404 |
| TrulicityDulaglutide | 24 | $33,438 |
| MyrbetriqMirabegron | 35 | $26,731 |
| VascepaIcosapent Ethyl | 37 | $25,431 |
| LinzessLinaclotide | 26 | $22,607 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Combivent Respimat | $163 | $321,866384 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort, Brilinta | $318 | $204,390206 claims |
| MerckJanuvia, Janumet | $35 | $187,259161 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $172 | $152,217209 claims |
| PfizerEliquis | $108 | $128,337137 claims |
| Novo NordiskOzempic, Rybelsus | $169 | $103,06087 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $76 | $52,28840 claims |
| AmgenProlia | $69 | $46,76727 claims |
| GileadVemlidy | $19,357 | $36,97224 claims |
| Astellas Pharma US IncMyrbetriq | $224 | $26,73135 claims |
| AbbVieLinzess | $158 | $22,60726 claims |
| Johnson & JohnsonXarelto | $93 | $22,07121 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 8,530 internal medicine providers in Florida.
Other internal medicine in Orlando
- Kwabena AyesuOrlando$27.6M
- Malisa AgardOrlando$12.2M
- Alfonso Gonzalez-RodriguezOrlando$4.7M
- Tatyana MiroshnikovaOrlando$4.2M
- Yaneicy Gonzalez RojasCoral Gables$93.5M
- Juan Carlos RondonHollywood$66.8M
- Jaynier MoyaPembroke Pines$45.4M
- Mark KutnerMiami$35.7M
- Gilberto JimenezHialeah$35.6M
- Mira BaronWest Palm Beach$29.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.